BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Provision for Sales Rebates & Returns Charged to Revenue by Year
Provision for Sales Rebates & Returns Charged to Revenue ($M) ($M)
BeOne Medicines Provision for Sales Rebates & Returns Charged to Revenue: $1,449M in FY2025, up 43.9% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Accrued Sales Rebates Rollforward Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Provision for Sales Rebates & Returns Charged to Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,449 | +43.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 1,007 | +90.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 529 | +187.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 184 | +60.1% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 115 | +626.6% | Form 10-K (filed 2023-02-27) ↗ |
| FY2020 | Dec 31, 2020 | 15.8 | +154.8% | Form 10-K (filed 2022-02-28) ↗ |
| FY2019 | Dec 31, 2019 | 6.20 | -13.9% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 7.20 | +80.0% | Form 10-K (filed 2020-03-02) ↗ |
| FY2017 | Dec 31, 2017 | 4 | – | Form 10-K (filed 2019-02-28) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Provision for Sales Rebates & Returns Charged to Revenue ($M), annual FY2017–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/gtn-provision
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.